Novavax vaccine demonstrates 90% efficacy, 100% protection against moderate, severe disease
Rajan Nath
June 14th 2021 06:17 PM --
Updated:
June 14th 2021 06:18 PM
The US company Novavax said that its COVID-19 vaccine, in the Phase 3 trial, demonstrated an overall efficacy of 90.4 percent against mild, moderate, and severe disease caused by the COVID-19 strain.
PREVENT-19 Phase 3 Trial, Novovax COVID-19 Vaccine Candidate Demonstrates:
- 90% overall efficacy
- 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest
- 91% efficacy in high-risk populations
- 100% protection against moderate and severe disease
- 100% efficacy against variants "not considered Variants of Concern/Interest"